Today's Top 5
5. Novel Immunotherapies for Renal Cell Carcinoma
Thrilled to have been able to work with co-first author @BraunMDPhD, mentors @DrChoueiri & @VanAllenLab, and the whole team on this review in @NatRevClinOncol on the prospects of immunotherapy in #RCChttps://t.co/GpRKlu7CO5 https://t.co/SydXIjKk0I pic.twitter.com/yVvr04vNkb
— Ziad Bakouny (@ZiadBakouny) January 12, 2021
4. ASCO Winter 2021 Quality Training Program Commences
Excited to begin our first session of @ASCO Winter 2021 #ASCOQTP program with our amazing multidisciplinary @WeillCornell team! @FrancieRNMBA @KJ8989 #qualityimprovement #oncology #advancedcareplanning
— Christine Garcia, MD, MPH (@christinemphmd) January 14, 2021
3. The Surgeon’s Role in the Treatment of Metastatic Melanoma
Just 2 weeks until @jzager99 joins @SurgeryUH for Grand Rounds! “The Surgeons Role in the Treatment of Metastatic Melanoma”
— Luke D. Rothermel (@LukeRothermel) January 14, 2021
@UHSurgOncology @UHSurgeryRes @MoffittNews @JoeSabik @JordanMWinterMD @SocSurgOnc pic.twitter.com/bayowL3ejY
2. What are the Out-of-Pocket Costs for Pancreatic Enzyme Replacement Therapy?
Pancreatic enzyme replacement therapy is often required to treat people with pancreatic disease #pancsm
— Arjun Gupta (@guptaarjun90) January 15, 2021
What are the out-of-pocket costs for a 30-day supply for Medicare beneficiaries?
Can be ~$1,000!!
This is out-of-pocket! For 1 month!
Check out our work at @ASCO #GI21 pic.twitter.com/oDZ2XxzBzw
1. Impact of Primary Tumor Sidedness in Early-Onset Colorectal Cancer
The impact of primary tumor sidedness on survival in early-onset colorectal cancer (EO-CRC) by stage: A National Veterans Affairs retrospective analysis. #GI21 @CCAlliance Left sided metastatic EO-CRC has better overall survival than right sided metastatic EO-CRC. pic.twitter.com/9DACx5Euxz
— Laura D Porter, MD (@DrLauraPorter) January 15, 2021